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This Bachelor’s thesis was made in research group which operates in the Laboratory of 
Molecular Oncology, at the Biomedicum, University of Helsinki, Finland. Bachelor’s thesis 
aim is to characterize of a new in vivo model of breast cancer lung metastasis. Research 
group has started their study recently and the study will continue further to cancer drugs.  
 
Cancer is a worldwide and common fatal disease. Cancer has been studied over time and 
is an important subject of research today. The studies over time have led to the discovery 
of new medicines and therapies to cancer. The origin of cancer is the due of many factors. 
Breast cancer is heterogeneous disease and it is the most common cancer in women. Breast 
cancer can be aggressive and metastatic which is related with poor prognosis. 
 
One of the important tyrosine kinase proteins in breast cancer is human epidermal growth 
factor receptor HER-2 and its overexpression is associated to cancer development. It acts 
as an activator in many signaling cascades and a part in cell growth, dividing, proliferation 
and cells repairing themselves. HER-2 is commonly used biomarker in the diagnosis of 
breast cancer, and it is also used in prognosis and treatment planning.  
 
Cytokeratins are composed of keratin proteins and expressed in all epithelial cells. Those 
are intermediate filaments in eukaryote epithelial cells and thus are part of the cytoskeleton. 
Cytokeratins are typically expressed in different types of carcinomas and cancer cases. Anti-
cytokeratins are specific markers for epithelial cell differentiation and are used as tools for 
the classification and identification of tumors.  
 
Tumor samples were stained using two-step immunohistochemical staining with two differ-
ent antibodies, HER-2 and Anti-Pan Cytokeratin. Immunohistochemical staining is an anti-
body-antigen method and positive result is shown as brown color. 
 
The results are based on immunohistochemical staining's shown in the figures. The charac-
terization has been implemented by describing the metastasis of tumors and their cell struc-
ture and comparing the two different antibody staining. I did the conclusions of the results, 
based on the theory of earlier studies. 
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Tämä opinnäytetyö on toteutettu tutkimusryhmässä, joka toimii molekulaarisen onkologian 
laboratoriossa, Biomedicumissa, Helsingissä. Opinnäytetyöni tarkoituksena oli karakteri-
soida rintasyövän keuhkometastaasien uutta in vivo-mallia. Syöpätutkimuksiin kohdentunut 
tutkimusryhmä on aloittanut tämän tutkimuksen vähän aikaa sitten, ja he jatkavat tutkimusta 
syöpälääkkeisiin. 
 
Syöpä on maailmanlaajuinen ja yleinen kuolemaan johtava sairaus. Syöpää on tutkittu ajan 
mittaan paljon, ja se on tärkeä tutkimuksen kohde. Aiemmin tehdyt tutkimukset ovat johta-
neet uusien syöpälääkkeiden ja hoitomuotojen löytämiseen. Syöpä on monen tekijän aiheut-
tama sairaus. Rintasyöpä on heterogeeninen sairaus ja se on naisilla yleisin syöpä. Rinta-
syöpä voi olla aggressiivinen ja metastasoiva, jolloin myös syövän ennuste on huonompi. 
 
Yksi rintasyövän tärkeistä tyrosiinikinaasiproteiineista on ihmisen epidermaalinen kasvute-
kijä reseptori 2 (HER-2) ja sen yli-ilmentyminen liittyy vahvasti syövän kehitykseen. Se toimii 
aktivaattorina monissa signalointikaskadeissa ja osana solujen kasvua, jakautumista, lisään-
tymistä ja solujen korjautumista. HER-2 on yleisesti käytetty biomarkkeri rintasyövän diag-
nosoinnissa, ja sitä käytetään myös syövän ennusteen teossa ja hoidon suunnittelussa. 
 
Sytokeratiinit koostuvat keratiiniproteiineista, ilmenevät kaikissa epiteelisoluissa ja ne ovat 
osa solun tukirankaa. Sytokeratiinit ovat siis väli filamentteja eukaryoottien epiteelisoluissa. 
Sytokeratiinit ilmenevät tyypillisesti erityyppisissä karsinoomissa ja syöpätaudeissa. Sytoke-
ratiinit ovat spesifisiä markkereita epiteelisolujen erilaistumiseen, ja niitä käytetään välineinä 
kasvainten luokittelussa ja tunnistamisessa. 
 
Keuhkometastaasien karakterisointiin käytin immunohistokemiallista värjäystä kahdella eri-
laisella vasta-aineella, HER-2:lla ja Anti-Pan-Cytokeratiini:lla. Immunohistokemiallinen vär-
jäys on vasta-aine-antigeenimenetelmä ja positiivinen tulos ilmenee ruskeana värinä. 
 
Tulokset perustuvat immunohistokemiallisiin värjäyksiin. Karakterisointi on toteutettu kuvaa-
malla metastaasikasvaimia, niiden solurakennetta ja vertaamalla kahta käytettyä vasta-ai-
nevärjäystä. Tein tulosten johtopäätökset aiemmin tehtyjen tutkimusten teoria pohjaan pe-
rustuen. 
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Abbreviations 
ABS Absolute alcohol 
 
Apoptosis Programmed cell death 
 
CK Cytokeratin 
 
DAB Diaminobenzidine 
 
DNA Deoxyribonucleic acid 
 
EGF Epidermal growth factor 
 
EGFR Human epidermal growth factor receptor 
 
ER Estrogen receptor 
 
EtOH Ethyl alcohol 
 
EU European union 
 
HER-1 Human epidermal growth factor receptor 1 
 
HER-2 Human epidermal growth factor receptor 2 
 
HER-3 Human epidermal growth factor receptor 3 
 
HER-4 Human epidermal growth factor receptor 4 
 
HRP Horseradish peroxidase 
 
IARC International Agency for Research on Cancer 
 
IHC Immunohistochemistry 
 
JIMT-1 Breast cancer cell line 
 
p53 Tumor suppressor protein 
 
PR Progesterone receptor 
 
TBS Tris-buffer saline 
 
TIFF Tagged Image File Format 
 
TP53 Coding gene for protein p53 
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1 Introduction 
This bachelor’s thesis was produced as a part of Mark Barok MD Ph.D. research project 
under his professional guidance. The group operates in the Laboratory of Molecular On-
cology, at Biomedicum, University of Helsinki, Finland and aims to establish novel in vivo 
models of metastatic breast cancer and test anti-cancer drugs with the model. Here, I 
show the optimization results of immunohistochemical labelling by utilizing key markers 
used to investigate the morphology of breast cancer metastases in mouse lung tissue 
and characterize the metastases based on the results.  
Cancer is a global disease and causes many deaths a year. Malignant, aggressive and 
metastatic cancer has the worst prognosis. Cancer and cancer treatments are commonly 
studied subject around the world. (World Cancer Research Fund. 2018.) Around 15–20 
% of breast cancers are HER-2 positive. HER-2 positivity is related to poor prognosis 
and, higher incidence of mortality, and therefore plays a role in treatment planning. Cy-
tokeratins are intermediate filaments in eukaryote epithelial cells and typically expressed 
in different types of carcinomas and cancer cases. Cytokeratins are used as markers in 
tumor diagnostics. HER-2 and cytokeratins are used to estimate the prognosis of breast 
cancer and the level of tumor aggressiveness. (Fletcher 2019; Karantza 2011; Mitri — 
Constantine — O’Regan 2012; Schweizer et. al. 2006.) 
The aim of my thesis is to characterize of a new in vivo model of breast cancer’s lung 
metastasis. During the study I used two different immunohistochemical staining antibod-
ies, compared the results of the both staining and described the metastatic tumors in the 
lungs of immunocompromised mice. All the samples are from different immunocompro-
mised mice injected with JIMT-1 carcinoma cancer cell line. I sliced sections from paraf-
fine embedded tumor blocks by microtome. Results are shown by images and they are 
descripted and summarized below. 
Immunohistochemistry is the main method used in this work. Immunohistochemical 
staining has been in use in diagnostics, planning treatment based on the cancer charac-
teristics, determination of the primary tumor origin for metastatic cancer, tumor classifi-
cation, identification of structures and as a disease prognostic biomarker. The staining’s 
in are including two different antibodies, which are also typically used in part of cancer 
diagnostics. (Duraiyan — Govindarajan — Kaliyappan — Palanisamy 2012.) 
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Mice are strongly involved in research, which underlines the importance of ethics. Mice 
are the most commonly used mammals in cancer and cancer drug studies. The ethics is 
important when study involves living beings and there are laws in Finland that control 
and prescribe research involving animals. There are also EU directives in Europe that 
regulate the use of animals. (Government Decree on the Protection of Animals Used for 
Scientific or Educational Purposes 564/2013; European Parliament and the Council of 
the European Union. Directive 2010/63/EU; Perlman 2016.) 
2 Theoretical starting points 
2.1 Cancer 
Cancer today is one of the most studied diseases worldwide and many different methods 
and variations have been used in cancer researches (Seyfried — Huysentruyt 2014). 
International Agency for Research on Cancer (IARC) points out in their global cancer 
data report (2018) that cancer is a global and very dangerous disease and over half of 
the cancer cases reported lead to death. Today the cancer incidence is related to the 
population aging and growth. The origin of cancer is the due of genetic changes and 
cancer is known to be caused by predisposing cells to substances possessing the ability 
to cause uncontrolled cell division, called carcinogens. Carcinogens include external fac-
tors as environment and lifestyle and internal factors as metabolism, age, and heredity. 
(Hanselmann — Welter 2016.) 
For functioning properly, the cell must occupy its correct position and divide if necessary 
and die through programmed cell death (apoptosis) when it is required. Thus, proto-on-
cogenes are essential genes for normal cellular function and their protein products are 
involved in many cell growth-regulating functions such as cell cycle regulation, apoptosis, 
and differentiation. A proto-oncogene may become an oncogene due to a point mutation 
that results in a continuously active protein product or excessive amplification of the 
proto-oncogene resulting in overproduction of the protein, or translocation causing higher 
expression of the protein. This oncogene activation typically results in increased cell di-
vision, decreased cell differentiation, and inhibition of apoptosis. In addition to oncogene, 
one or more of the tumor suppressor genes must stop working properly, and for that it 
needs damages in both gene copies in the cell for uncontrolled proliferation. Tumor sup-
pressor genes are the ones which in normal circumstances slow down cell division, con-
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tribute to the DNA mistake repair process, or leads the cell to apoptosis (American Can-
cer Society 2014). An example of tumor suppression genes is TP53 which encodes the 
p53 protein, which in turn participates in cell cycle regulation by stopping the cell cycle if 
its DNA is damaged. Thus, if p53 is inactivated, the cell will continue to divide, even if 
the DNA is damaged, and the cell divides. The daughter cells formed by cell division do 
not have the correct number of genes, and they can harbor new mutations caused by 
DNA damage or its not-appropriate repair. Therefore, activation of oncogene and inhibi-
tion of the tumor suppressor genes leads to the survival of the cell instead of apoptosis. 
When the cell has these genetic defects, it is allowed to divide uncontrollably and create 
new daughter cells with the same abnormal behavior and abnormal structure, then can-
cer can occur. (Alberts et.al. 2004: 726-733; American Cancer Society 2014; Bray et. al. 
2018; Chial 2008; World Cancer Research Fund 2018.)  
Breast cancer is heterogeneous disease and the most diagnosed and common cancer 
in women. It causes many deaths and has been in 2018 the second most common cause 
of cancer deaths. Breasts contain luminal cells in the inner part and myoepithelial (basal) 
cells in the outer part. Histopathological classification in breast cancer cases are based 
on gene expressions profiling. Basic molecular subtypes of breast cancer are Luminal A, 
Luminal B, HER-2-enriched and basal-like. Each subtype has been shown to differ in 
incidence, prognosis, response to treatment, preferential metastatic organs, and recur-
rence or disease-free survival outcomes. Basal-like is a unique subtype among breast 
cancers and it is usually triple negative breast cancer, which means estrogen receptor 
(ER) -negative, progesterone receptor (PR) -negative, and HER2-negative. It has the 
worst prognosis and worse outcome than Luminal-A or Luminal-B subtype. However, 
Martin-Castillo et al. has shown in their study that there is basal-HER-2+ subtype which 
is associated with basal-like subtype. This basal-HER2+ subtype is positive for basal 
cytokeratins as well. (Cho 2016; Bray et. al. 2018; Martin-Castillo et. al. 2015.) 
2.2 Metastasis 
Once the cancer cell is formed it begins to differentiate and divide uncontrollably forming 
a primary tumor. A tumor is malignant when the cells invade the surrounding tissue. Due 
to this invasion, malignant cells may leave the primary tumor and be transported via the 
lymphatic or circulatory systems and might form a secondary tumor, called metastasis, 
that proliferates elsewhere in the body. Metastases are generally responsible for cancer 
deaths worldwide, and this high mortality rate is the main reason, why cancer studies are 
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so important. An example in metastatic malignant breast cancers the cancer cells in-
vades surrounding tissue, and cells transport through the lymphatic system into the 
lymph node and then into the lungs thereby forming lung metastasis. Usually, metastatic 
cancer is associated with poor prognosis and a higher risk of mortality in cancer cases. 
However, the cells in the metastases are similar to the origin of the primary tumor. Thus, 
this means that if breast cancer metastasizes to the lungs, the secondary tumor consists 
of breast cancer cells, not abnormal lung cells. The tumor in the lungs is then called 
metastatic breast cancer, not lung cancer. (Alberts et.al. 2004: 726-733; Seyfried — 
Huysentruyt 2014; Martin — Ye — Sanders — Lane — Jiang 2013.) 
2.3 The JIMT human cancer cell line and mice model 
In a study Tanner et al. (2004) created a carcinoma cell line (JIMT-1) from pleural me-
tastases from a 62-year-old breast cancer patient. The patient was clinically resistant to 
trastuzumab. The established cell line has the amplification of the HER-2 oncogene and 
it is resistant to trastuzumab both in vitro and in vivo mouse models, which provides a 
good model for example studies of trastuzumab resistance mechanisms. Consequently, 
the JIMT-1 is a human HER-2- positive breast cancer cell line which has been in use at 
earlier in the research group’s studies. In this project cell culture was done in Biomedi-
cum, Helsinki, in cell culture room by one of research team member. For this research, 
immunocompromised mice were injected intravenously with 100 000 JIMT-1 cells. JIMT-
1 should be cytokeratin positive and Tanner. et al. has shown it has been positive for 
specific CK8, CK18, CK5 and CK14 cytokeratins. 
Immunocompromised mice are commonly used models in cancer and cancer drug re-
searches. Mice models can closely mimic, for example, human epithelial carcinogenesis, 
which provides ample scope for in vivo studies. Mouse models represent cellular and 
molecular changes in cancer and therefore play a crucial role in cancer studies and can-
cer medication studies. Despite, immunocompromised mice are used to study tumors, 
uncertainties may arise due to the inability to ensure tumor initiation and rate of develop-
ment. Immune deficiency is one of the risk factors for cancer and immunocompromised 
mice how they express T cells, B cells, and macrophages, and NK cells. In this experi-
ment we used nude mice which have no T cells but have B cells, and macrophages, and 
NK-cells. The advantage of using mice models is that it gives better opportunities to 
investigate many cancer-related biological process and also an effect of drugs in a living 
organism, which is much more complex than the in vitro experiments and closer to the 
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real situation of a patient with metastatic cancer. (Lei — Ren — Wang — Liang — Tang 
2016.) 
2.4 HER-2 
The human epidermal growth factor receptor 2 (HER-2), is a tyrosine kinase and is a 
transmembrane protein on the cell surface. HER-2 is able of intracellular signalling and 
acts as an activator in many signalling cascades. It amplifies signals from other members 
of the epidermal growth factor receptor (EGFR) family (HER-1, HER-3 and HER-4). Ad-
ditionally, activation of HER-2 also causes changes in gene expression mediated by 
transcription translation and protein stability. Due this activation, HER-2 acts part in cell 
growth, dividing, proliferation and cells repairing themselves. However, if HER-2 is ab-
normal and overexpressed in the cell membrane it causes an uncontrolled rate in cell 
growth, and proliferation. The EGFR family, including epidermal growth factor receptors 
HER-1, HER-2, HER-3 and HER-4, is one of the most characterized systems in breast 
cancer. HER-2 is overexpressed in 15–20 % of breast cancers and HER-2 overexpres-
sion has been shown to occur also in other cancers such as lung, gastric, oral and ovar-
ian cancers. (Barok et.al. 2018; Fletcher 2019; Mitri et. al. 2012; Meric-Bernstam — Hung 
2006.)  
Breast cancer can have HER-2 gene amplification, and this can lead to a significant 
amount of HER-2 receptor expression at the tumor cell surface (Moasser 2011). HER2 
positivity is one of five major biologically intrinsic subtypes in breast cancers. HER-2 
positive cancer is a more aggressive disease, with a higher relapse rate and increased 
mortality. Trastuzumab is an anti-HER-2 monoclonal antibody drug used to treat HER2 
positive breast cancer and gastric cancer, in combination with chemotherapy and it has 
been shown to be effective and improve the prognosis (Slamon et. al. 2001). 
Trastuzumab has been used since 1998 for the treatment of HER-2 positive metastatic 
breast cancer. (Mitri et. al. 2012; Meric-Bernstam — Hung 2006). In breast cancer diag-
nostics, HER-2 staining is part of tumor classification, which is based on morphology and 
molecular proliferations, and it also helps with prognosis and planning the treatment for 
cancer to avoid mortality. (Minot et. al. 2012) 
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2.5 Cytokeratins 
Intermediate filaments composed form keratin proteins in eukaryote epithelial cells are 
known as cytokeratins (CK). They are expressed in all epithelial cells and are part of the 
cytoskeleton. Cytokeratin expression in the cell depends on the time of cell differentiation 
and the stage of development. There are two types of cytokeratins: acidic type I (9–23) 
and basic type II (1–8). Humans have 30 different genes which are encoding cy-
tokeratins; 20 are epithelial genes and the rest 10 are specific for trogocytosis. Trogocy-
tosis is also called immunological synapse and it refers to the cell-cell interaction of an-
tigen presenting cells. In cells, cytokeratin forms a complex network in the cytoplasm, 
and it extends from the nucleus to the cells surface, supporting the nucleus and the cell 
itself. They play an important role in epithelial cells protected from mechanical and non-
mechanical stress factors, and their important functions in cells include mobility, cell size, 
protein synthesis and membrane signalling. Phosphate exchanges take place in the cy-
tokeratin network and mediate depolymerization, which in turn affects mitotic, post-mi-
totic division, cellular movement and differentiation. (Schweizer et. al. 2006; Gusterson 
— Heath — Ross — Stein 2005; Rechavi — Goldstein — Venitsky — Rotblat — Kloog 
2007.) 
Cytokeratins are typically expressed in different types of carcinomas and cancer cases. 
The expression or absence of cytokeratin in tumors and peripheral blood is prognostically 
significant in cancer cases and they have been widely and long in use as immunohisto-
chemical markers in tumor diagnostics. Cytokeratins are involved in cancer cell invasion, 
metastasis and sensitivity to cancer treatment. Cytokeratins can be used to determine, 
for example, the prognosis of breast cancer and the tumor aggressiveness of cancer. 
Epidermal growth factor receptor and certain cytokeratin positivity are associated with 
high tumor levels and poor prognosis of cancer. The cytokeratins commonly expressed 
by breast cancer are CK5, CK6, CK7, CK14, CK17, CK18 and CK19. (Gusterson et. al. 
2005; Karantza 2011.) 
Anti-Pan Cytokeratin antibody diluent is specific for Type I (10, 14, 15, 16 & 19) and Type 
II (1, 3, 4, 5, 6 & 8) cytokeratins and it recognizes epitopes which are present in most 
human epithelial tissues. Anti-cytokeratins are specific markers for epithelial cell differ-
entiation and are used as tools for the classification and identification of tumors. In this 
Anti-Pan Cytokeratin staining was used as positive control human skin tissue samples 
and as negative control mouse spleen tissue samples. This antibody reacts with human 
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cytokeratins. (Karantza: 2011. Appendix 2.) In cancer, cytokeratins are used as tumor 
markers in diagnostics because malignant tumors partially maintain specific keratin pat-
terns associated with the original cells. The used cancer cell line was human breast can-
cer and healthy breast cells contain cytokeratins, so staining was used to experiment 
whether cytokeratin is also present in metastases. (Karantza 2011.) 
2.6 Principle of Immunohistochemical staining 
Immunohistochemical (IHC) methods are widely used in clinical diagnostics and re-
search laboratories to determine the distribution of monoclonal and polyclonal antibodies 
in tissue sample slides. IHC staining has been increasingly used since the 1980s to de-
tect the presence and location of specific proteins in a tissue section. The method has 
been used manually for a long time and nowadays automated alternatives are also avail-
able. The IHC method has applications in diagnostics, planning treatment, determination 
of the primary tumor origin for metastatic cancer, tumor classification, identification of 
structures and as a disease prognostic biomarker. (Luongo De Matos — Trufelli — Lu-
ongo De Matos — Da Silva Pinhal 2010.)  
The staining is based on antibody-antigen binding and the principle of the technique is a 
specific antibody that will bind with its specific antigen to give an antibody-antigen com-
plex. IHC methods can be either chromogenic or fluorescent. Chromogenic staining is 
visible by a light microscope and for fluorescence, the antibody is conjugated to a fluor-
ophore that is detected by a fluorescence microscope. In the chromogenic staining the 
binding can be visualized by enzyme and in this work was used indirect detection. Indi-
rect detection is a two-stepped process where the primary antibody binds the target an-
tigen and enzyme-labelled secondary antibody binds to the primary antibody which is 
already bound to the antigen that can be visually detected. (Aptum Biologics; Duraiyan 
— Govindarajan — Kaliyappan — Palanisamy 2012.) 
Tissues from sources need to be preserved quickly in order to prevent cellular protein 
and tissue degradation. Acetone, formalin or methanol may be used for fixation, depend-
ing on the target antigen. Formalin is a covalent crosslinking reagent that is commonly 
used as a fixative, and the attachment time depends on the degree of fixation desired. 
Tissues fixed in formalin are typically embedded in paraffin wax. Fixation keeps tissue 
shape, cell structure sharp and prevent endogenic and exogenic enzyme activity. Tissue 
sections need to be attached to glass slides that are suitable for immunohistochemical 
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staining. Methods used to determine the antigens in the tissue with the employment of 
specific antibodies that can be visualized through staining. (Luongo De Matos et. al. 
2010.)  
With formalin fixation, antigen epitope exposal is essential to allow the antibodies to bind. 
Usually, formalin fixation generates methylene bridges which are cross-linking proteins 
and thus mask the target epitope. The commonly used heat-induced antigen retrieval 
breaks the methylene bridges and exposes the epitope thereby allowing antibodies to 
bind. Chromogenic detection is based on antibodies conjugated to enzymes, such as 
commonly used horseradish peroxidase (HRP), to generate a color-producing reaction. 
When HRP is used, the activation of endogenous enzymes should be prevented to avoid 
the formation of nonspecific binding. Antibodies are diluted in an antibody buffer that 
helps stabilize the antibody and when the antibody is incubated it can bind to the target 
antigen in the sample. Antibody buffer can decrease non-specific binding. HRP binds to 
the antigen-antibody complex forming an antigen-antibody-HRP complex which reacts 
with DAB substrate when it is incubated correctly and forms the brown colour. Diamino-
benzidine (DAB) is a chromogen for HRP and it is forming brown color which is insoluble 
in alcohol or water. Counterstaining with Hematoxylin is performed after antigen staining 
to create contrast and thus facilitate the visibility of the antigen and distinguish the stain-
ing result from the rest of the tissue. Hematoxylin gives a blue coloured counterstaining 
result to negative tissue. (Abcam. IHC-Paraffine; Luongo De Matos et. al. 2010; Paulsen 
— Dimke – Frische 2015.) 
2.7 Cross-reaction in immunohistochemical staining 
Cross-reactivity refers to the binding of a secondary antibody to a non-target antigen. 
The secondary or primary antibody can show an affinity for identical or similar epitopes 
on non-target antigens. A high primary antibody concentration will increase these inter-
actions between the primary antibody and non-target epitopes and increase nonspecific 
binding and background staining. Polyclonal antibodies are more likely to cross-react 
and generate non-specific signal than monoclonal antibodies. Anti-Pan Cytokeratin is a 
monoclonal antibody so that cannot explain the cross-reaction. Cross-reactivity of spe-
cies is also possible. The antigen-binding site of an antigen then recognizes immuno-
globulin from one species, and it may also detect a homologous epitope in the immuno-
globulin of another species. However, the solution for cross-rection is to reduce the con-
10 
 
centration of the antibody. Another consideration that has been shown is that the anti-
body diluent should contain sodium chloride because it helps reduce ionic interactions 
and normal antibody diluent (ImmunoLogic) is containing it in this case. (Abcam. Im-
munohistochemistry; ThermoFisher. IHC troubleshoot guide.) 
3 The study aims and purpose 
The aim of this study is to establish and characterize a human, HER2-positive breast 
cancer lung metastasis model in immunocompromised mice. Characterization is based 
on images obtained by immunohistochemical staining. Later, the research group intends 
to use this model for studying the effect of different drugs in this model. Immunocompro-
mised nude mice have been inoculated intravenously with HER2-positive human breast 
cancer cells (JIMT-1) to generate metastasis in the lung. The research includes an im-
munohistochemical comparison of the metastasis to the primary tumor and to the paren-
tal cells growing in the cell culture laboratory. This bachelor’s thesis contains information 
on the cellular structure of human breast cancer cells and determines the role of certain 
proteins and receptors in the cells and cell membranes. The research group intends to 
establish cell lines from the lung metastases. 
Leading research task of the thesis: 
- Characterizing of a new in vivo model of breast cancer lung metastasis using 
immunohistochemical staining methods.  
4 Methods and throughput 
4.1 Tumor samples and preparation of slides 
The JIMT-1 cells were cultured in a cell culture laboratory and injected into immunocom-
promised nude mice. The mice were sacrificed 17 weeks after the injection, and then 
samples from the lungs were collected and fixated. Mice sacrifices followed ethical prin-
ciples, and all those who work with them have received separate training in animal-re-
lated researches. All the tumor samples are from different mice and samples were fixated 
in 4 % formalin at least 4 hours but not longer than 24 hours, and then processed with 
the automated tissue processing device. All the tissues were processed with automated 
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tissue processing device, operated in a separated laboratory in Biomedicum. After that 
tissue samples were embedded with paraffin wax forming paraffine blocks. Other mem-
bers of the research group were doing tissue sample fixation, processing, and paraffin 
embedding. All the samples which are in use are from immunocompromised mice. Tumor 
samples were collected from mice and fixated correctly. 
Slides were written by using a Primera Signature Slide Printer. The slides were placed 
in the printer, and a computer program is used to write the desired information on the 
frosted ends of the slides. Slides contained the information of sample tissue, identifica-
tion information of the sample, information of which staining and its dilution, used incu-
bation time, date when the sections and staining were made, and slide printer also added 
2D bar codes to slides. Before staining I made sections of the paraffin-embedded tumor 
sample blocks with a Leica RM2255 automated microtome. I used the fully automated 
microtome manually. In order to get optimal sections, the blocks need to be cooled before 
slicing them. The cooling helps with making the sections and from cooled blocks, the 
sections are whole and smooth. I sliced 3–4 µm thin sections from the blocks and first I 
moved the slides to cold water with using small brushes and then I took the section to 
IHC method accepted glass slide and dipped it into hot water (55 °C) where the section 
stretches and it can be placed to the slide smoothly and directly.  
4.2 Immunohistochemistry (IHC) 
In this process, immunohistochemically methods contain two different antigens. Both 
IHC staining is using the same leading base method. I was using the Abcam IHC-Paraf-
fine protocol to support the staining instructions from the lab. To prevent any interfer-
ences in staining results, paraffine needs to be removed carefully. Paraffin removal from 
the slides was accomplished as follows: slides in the xylene for 10 minutes then another 
vessel of xylene for 5 minutes and last xylene and absolute alcohol (ABS) dilution 50:50 
for 3 minutes. Then begins xylene removing and rehydrate phase within decrease alco-
hol series where the slides will be about 10 dips of each vessel, it includes two ABS 
vessels, two 96 % ethyl alcohol (EtOH) vessels, one 70 % EtOH and one 50 % EtOH 
vessels and the phase will end in Aqua vessel. The rehydrate phase is important be-
cause IHC staining is happening in hydrous media and is removing hydration from the 
sample (Thermo Fisher. Antigen retrieval). 
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Hydrogen peroxide processing lasted 30 minutes, and hydrogen peroxide dilution was 
made with 5 ml 35 % H2O2 and 200 ml Aqua. Hydrogen peroxidase inactivates endoge-
nous peroxidase which will prevent the non-specific background staining (IHCWORLD 
Peroxidase). Hydrogen peroxide dilution needs to be washed away with aqua after its 30 
minutes incubation.  
The antigen detection was implemented setting the slides to sodium citrate buffer pH 6 
and running slides with Retriever the minimum 2 hours’ time. Retriever heat up the slides 
in sodium citrate buffer and antigen is revealed within it and an antibody can access to 
the target. The slides must let cool down after Retriever handling and the sides are 
moved to slide holders under the aqua. Washing with Tris-buffered saline (TBS) solution 
is needed because the aqua should be washed away and to same time let you know the 
liquid will flow at the same speed within each slide holder. If the liquid passes through 
too fast when the antigen will be added to it, it’s not going to fix in the slide even if the 
incubation time will be right. TBS washing is done two times and each time the minimum 
effect time is 5 minutes and notice liquid must be flown past the slide holder before the 
next wash or next phase.  
In this phase, the specific antibody will be mixed to normal antibody diluent and mix were 
added to the slides. There are two different antibody diluents in use, 1:100 anti-HER-2 
and 0,1 µg/ml Anti-Pan Cytokeratin. I used 30 minutes of incubation time within all im-
plemented HER-2 staining. At first, I tried once overnight incubation, but the results were 
the same within 30 minutes incubation and overnight incubation, so I ended up doing the 
staining with 30 minutes incubation. The Anti-Pan Cytokeratin incubation time was over-
night, so I started incubation right before I left from work and continued at the next morn-
ing. After incubation time there is needed to do TBS washing, also two times and within 
5 minutes effect time for each. 
After antibody incubation and TBS washing, it was time to add WellMed Orion, detection 
system to the slides, 100 µl for each and it needs 30 minutes incubation time. HRP De-
tection system detects primary antibody bound to an antigen in mice tissue sections and 
eliminates the backgrounds by blocking protein-protein interactions in IHC staining and 
stabilize the antibody and this way it ensures a better staining result. After the peroxidase 
detection system, it is time to do TBS to wash away the detection system from the slides. 
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ImmPACT DAB is the name of the product which is produced by Vector (2019) and the 
dilution was 1 ml ImmPACT DAB-diluent and 1 drop of DAB and it produces in the sam-
ples a brown color by reacting with HRP. The incubation time which I used was 5 
minutes. Incubation time was in use at the research group and it is important to be the 
same at all staining’s. ImmPACT DAB was washed away with TBS washing diluent 5 
minutes and two times and before the next phase, I moved the slides to the aqua vessel. 
DAB is a carcinogen so it must be disposed of within dangerous garbage protocol. When 
I was handling this product, I used nitrile gloves and a lab coat to protect against skin 
contact. 
For counterstaining, Mauer’s hematoxylin was used in these two IHC staining methods. 
Slides were in Mayer’s hematoxylin precise 1 minute. If the slides are in dye too long, it 
could give over the stained outcome and it will be amiss to the staining result. Straight 
after Mayer’s hematoxylin, the slides were under running water 10 minutes and that 
washes away all the extra color. After Mayer’s hematoxylin and running water the slides 
were handled with rising alcohol series again 10 dips for each. Series contains 50 % 
EtOH vessel, 70 % EtOH vessel, two 96 % EtOH vessels, two ABS vessels, 50:50 ABS 
and xylene dilution vessel for three minutes, and two xylene vessels for five minutes and 
10 minutes. When the slides are in the last xylene vessel, I transferred it to another fume 
hood with a lid and I lifted the slides onto the blotting paper. Then the slides were covered 
using the three little drops of the glue on the cover glass and sliding it over the slide. 
After cluing the cover glasses to the slides, I left them to dry at least one day. 
The dyed slides were pictured by using SlideStrider (SK-100) automated microscope 
scanner. An automatic microscope scanner was in use during the whole working. The 
slides were placed to the rack and the automatic microscope scanned the slides on its 
own. Automatic scanning took a lot of time and usually I started the microscope to scan 
the slides when I left work, so they were ready when I returned in the morning. I used 
the Fuji ImageJ program to process and cut the images with my own. This program was 
in use because that was a free and easy use program that could process (TIFF) tagged 
file format images.  
The primary antibody may lose affinity for the target antigen due to long-term storage or 
freeze and thaw cycles. Also, changes in pH could cause this loss of affinity and that is 
why antibody diluent should always be ensured pH 7–8 which is optimum to antibody 
binding. Both antibodies were separated into small aliquots in sterile tubes and stored in 
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a freezer. That helped to avoid freeze and thaw cycles because whenever I made stain-
ing, I took only one small tube of antibody out of the freezer and made the right concen-
tration mixture. I used universal IHC-blocking diluent, pH 7.3 which is optimal to antibody 
binding. I used control slides every time I stained samples. For the immunohistochemical 
staining of HER-2, we used an anti-human HER-2 specific rabbit IgG as a primary anti-
body. Human skin was used for negative control and OE19 human HER-2 positive gas-
tric cancer xenograft was used as a positive control. Anti-Pan Cytokeratin staining we 
used human skin tissue as positive control and mice spleen as a negative control. 
4.3 Optimizing Anti-Pan Cytokeratin staining 
Anti-Pan Cytokeratin staining was introduced during my work and I optimized the staining 
with this antibody before staining the tissue sample slides. Anti-Pan Cytokeratin staining 
optimizing started from the incubation time. Concentration optimizing started from ana-
lyzing the 0,3 µg/ml and 0,5 µg/ml staining outcome because manufacturers product 
datasheet recommends 0,25 µg/ml–0,5 µg/ml concentrations (Abcam. Anti-Pan Cy-
tokeratin Antibody; Appendix. 2). The first staining was done within concentrations 0,3 
µg/ml and 0,5 µg/ml together with 1-hour and overnight incubations. Samples were the 
same with both concentrations and incubations, so the difference was easier to see. 
Overnight incubation was optimized for Anti-Pan Cytokeratin staining because from the 
staining results it is easy to see that overnight incubation is better and smoother than 1-
hour incubation results. After first staining, it’s sure that 0,5 µg/ml is too high concentra-
tion because the samples were strongly discolored so it was needed to find the perfect 
concentration for staining. When the staining result is over stained it’s harder to differen-
tiate the cells and tissue fragments. However, the best option was to do smaller concen-
trations than 0,3 µg/ml because within 0,3 µg/ml concentration stained sample slides 
were strongly stained too. The next staining was with 0,1 µg/ml, 0,2 µg/ml and 0,3 µg/ml 
concentrations and the samples which I stained were the same as in the first try. The 0,3 
µg/ml was taken along to the lower staining to give a reference to lower concentrations.  
5 Results 
5.1 Optimizing 
The results of the Anti-Pan Cytokeratin staining optimization are reported based on the 
figure below. I will tell more about the results and how the right staining concentration 
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was reached. Doing the optimizing of Anti-Pan Cytokeratin, it was shown clearly that 
within high concentration there were more cross-reaction than within a lower concentra-
tion. 
 
 Positive human skin controls and negative mice spleen controls for Anti-Pan Cy-
tokeratin staining, with different diluent ratio concentrations.  
In figure 1 first row images are positive human skin controls with diluent ratio concentra-
tions (a.) 0,1 µg/ml (b.) 0,2 µg/ml (c.) 0,3 µg/ml and second row are negative mice spleen 
controls and diluent ratio concentrations (d.) 0,1 µg/ml (e.) 0,2 µg/ml (f.) 0,3 µg/ml. The 
outcome was to optimize the Anti-Pan Cytokeratin staining to the 0,1 µg/ml concentration 
because of the staining results of slides that were stained within 0,1 µg/ml concentration 
were good, smooth and stained enough. Within 0,2 µg/ml concentration the staining re-
sult was over okay but it was giving some false positive epitopes in mice tissue and within 
0,3 µg/ml the dying was overdyed and mixed so in the negative control there was a little 
positive brown dyed spot’s in it. Anti-Pan Cytokeratin mixture was showing false positive 
epitopes in mice tissue, even if it should not. Concentration 0,1 µg/ml was the best be-
cause it was not giving false positive epitopes in mice tissue and the staining result was 
good and not over dyed (figure 1). 
We optimized the Anti-Pan Cytokeratin staining because the research group had not 
previously used this staining. Optimization is important to achieve the best possible stain-
ing result and thus all future staining can be performed at the same concentration, which 
increases results reliability. The optimization was successful and did not require many 
staining times to complete. 
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5.2 Controls 
Here is shown only the controls I used to stain the samples shown in the results. The 
controls are shown in the figures and opened in the text more below. Controls are im-
portant to achieve reliable results. 
 
 Control samples from HER-2 staining. 1 and 3 are negative controls (human skin), and 
2 and 4 positive controls (HER-2 positive gastric cancer xenograft). 
Negative control is human skin tissue and positive control is 96LuOE19 sample which 
were found to be a good control before I started working. 1 and 2 were controls are from 
staining tissue samples 218 JIMT and M1 JIMT. Those images are not zoomed but result 
color is visible from further too. In the image (1) human skin tissue is completely blue 
colored which means it is a negative control. Image 3 and 4 were control samples for 
tissue samples 235 JIMT, 236/1 JIMT, 236/2B JIMT and 234. In human skin tissue there 
is not any HER-2 and that is why it is good choice to negative control sample. 96LuOE19 
positive sample is strongly positive and the staining result is smooth. In any of these 
control samples there was not any dye clumps nor cross reaction visible. (Figure 2.) 
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 Control samples from Anti-Pan Cytokeratin staining. 
I made all Anti-Pan Cytokeratin staining’s with 0,1 µg/ml concentration and overnight 
incubation. In this staining human skin tissue sample and mice spleen tissue sample are 
used as positive and negative controls, respectively. In Figure 3 images 1 and 2 are 
controls from staining 218 JIMT, 234 JIMT and M1 JIMT samples. Images 3 and 4 served 
as a control samples from staining 235 JIMT, 236/1 JIMT and 236/2B JIMT samples. It 
is shown in Figure 3 that image 3 is slightly lighter in staining result than image 1. Staining 
results are visibly smooth and there were no markable dye clumps nor patch’s shown in 
control samples.  
5.3 Descript of tumors and comparing the staining’s 
JIMT-1 human breast cancer cell line was included in this work. The JIMT-1 cell line is a 
human breast cancer cell line, which is positive for HER-2 (Tanner. Et. al. 2004). All the 
used samples were mice lung tissue samples; the mice had been previously inoculated 
intravenously with the human JIMT-1 breast cancer cells. The mice lung tissue has neg-
ative staining result for HER-2 antigen as the antigen used has specific reactivity for 
human origin HER-2. Consequently, if we detect HER-2-positive cells in the mouse 
lungs, those should be human JIMT-1 breast cancer cells that metastasized the mouse 
lung. 
I compared the results of two different staining and I also describe the morphology of 
metastasis tumors based on figures. I used two IHC methods and as the table 1 shows 
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there were two positive samples 218 TUMOR LUC and M1 JIMT LUC within both anti-
gens and one which was negative within both 235 1/L JIMT. Two samples were positive 
within one antigen staining and negative within other 236 1/L JIMT and 236 2/B JIMT. 
Table 1. This table shows all the used sample blocks and them IHC staining results. 
Sample Block Tissue HER-2 Anti-Pan Cytokeratin 
218 TUMOR LUC LUNGS pos. (+) pos. (+) 
M1 JIMT LUC LUNGS pos. (+) pos. (+) 
236 1/L JIMT LUNGS pos. (+) neg. (-) 
236 2/B JIMT LUNGS neg. (-) pos. (+) 
235 1/L JIMT LUNGS neg. (-) neg. (-) 
234/2 JIMT LUNGS pos. (+) neg. (-) 
 
The results are shown by the images which I took from stained slides. Characterizing of 
lung metastasis and comparing these two different staining results is based on the im-
ages below. The controls of the all done IHC staining’s was shown and processed in the 
methods chapter in figure 1 and figure 2. In both staining’s brown color means positive 
and blue color negative for antibody. 
5.3.1 218 TUMOR LUC 
The results of Sample 218 JIMT, HER-2, and Anti-Pan Cytokeratin staining are shown 
in the figures below. I have described the results based on the images and compared 
the two different staining results. 
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 Sample 218 TUMOR LUC. HER-2 staining. Labeling A-H is naming the different me-
tastases. 2-8 are zoomed images from different metastases.  
As shown in figure 4 all the metastases have sharp boundaries and there are many dif-
ferent sized metastases in sample 218 TUMOR LUC. The color difference is clear in all 
images because cancer tissue is strongly positive for HER-2, and negative resulted tis-
sue is well stained also. First and second images are from far and those are more like 
an overview of the whole sample and other images 3–8 are zoomed images. In this 
sample JIMT 218 there are eight different sized metastases which can be illustrated. The 
smallest one (E) is zoomed in image 3. There were two micro metastases (C) and (E), 
two small metastases (D) and (H), three medium-sized (B), (F) and (G) and one bigger 
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metastasis(A). The sample 218 TUMOR LUC is clearly strong positive for HER-2 protein 
in figure 4. 
Metastases (C) and (E) were mini sized I assume they are under 100 cells sized. In both, 
the cells are densely organized, and the staining result is strong as shown example in 
figure 4 image 3. (D) and (H) metastases were small sized, and the cells are slightly 
more widespread than in the mini sized metastases, but still characteristic dense and 
abundant cell dividing is visible in images 5–8. In tumor (D), which is zoomed in images 
6 and 8, there is visibly a negative site in metastasis and around it the tumor is positively 
stained. The negative site is also dense from cell organization and clearly associated 
with positive sites in metastasis and the it is clearly a part of the metastasis structure. 
The cell size of all metastases is similar, and the metastatic cells are larger than the lung 
tissue around them. Cell size have variation and it is visible in image 6. (Figure 4.)  
 
 Sample 218 TUMOR LUC with Anti-Pan Cytokeratin staining. Images are zoomed from 
different metastases. 
As figure 5 shows the images are zoomed of different metastases. Sample was at this 
point almost sliced to the end, so it is a bit split. Sample 218 JIMT is obviously positive 
for Anti-Pan Cytokeratin. The staining result of this Anti-Pan Cytokeratin staining is not 
as strong as HER-2 staining result. The metastases lining is sharp and clean as in the 
other staining, but the color is more faded. Smaller metastases as example in image 3 
are more strongly dyed than the bigger metastases and in the bigger metastases the 
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edges are also more strongly stained than centers. In figure 5 image 1 Is zoomed image 
from the biggest metastasis. Image 2 is the same as metastasis (F) in figure 4. 
In figure 5, image 3 there is sharp border between negative site and positive site of that 
tumor and positive cells at the borderline are clearly distinguished. In figure 5, image 2 
metastasis is shown also cytokeratin negative area in it. The negativity is in edge of the 
metastasis and small part in center of it, this is the same one as in figure 4, (F) metasta-
sis. It is visible that the negative site is part of tumors structure because of the organizing 
of the cells appears to be similar.  
Image 3 in figure 5 is shown the metastasis (D) from figure 4. and both staining’s for the 
sample 218 TUMOR LUC have negatively stained site in the tumor, and the site is lo-
cated to the same place. The two images of the tumor are inverted relative to each other 
which may be a bit confusing, but if you take a closer look at the structure of the tumor 
then you may notice that it is at the same point.218 TUMOR LUC sample had the best 
staining result in both staining’s. There was sharp lining between healthy and metastasis 
cancer tissue. This sample has eight metastases and indicates that the cancer has me-
tastasized well to the lungs as desired. 
5.3.2 M1 JIMT LUC 
Below are the results of sample M1 JIMT LUC with HER-2 and Anti-Pan Cytokeratin 
staining. The description and presentation of the results are based on the figures and I 
have compared the results of two different staining. 
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 Sample M1 JIMT LUC. HER-2 staining. 1. Whole sample slide is shown. 2. Zoomed 
image of second biggest metastasis. 3. Zoomed image from biggest metastasis in the 
sample. 4. Zoomed image from the smallest metastasis. 
In sample M1 JIMT LUC there were three different sized metastases in the mice lungs. 
Metastases are shown a variation cell size. There were one big (A), one medium sized 
(B) and one small (C) metastasis. The staining result is positive, well stained and bor-
dering of the metastases are sharp in this sample. Positive, brown colored metastases 
are clearly distinguished from negative, blue colored lung tissue. As seen in figure 6, lung 
tissues cellular structure is more loose connective tissue than metastases, where tissue 
is tight connective. Medium sized metastasis (B) in image 2 is sharp bordered and having 
a tight cell structure and it is the densest of the metastases.  
 
  Sample M1 JIMT LUC. Anti-Pan Cytokeratin staining. 
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Sample M1 JIMT LUC is positive for Anti-Pan Cytokeratin staining. In figure 7 the 
zoomed image 3 of metastasis shows that cancer cells and healthy tissues lining is clear 
and sharp lining. The metastases are similar structure in this figure 7 than in HER-2 
staining of the same sample in Figure 6 and all the same metastases are stained positive. 
Staining result is good compared to controls and based on staining of positive metasta-
ses and negative lung tissue.  
Sample M1 JIMT was also strongly positive for both staining’s and as sample 218 JIMT 
the both staining’s metastases were visibly stood out well. All the metastases were well 
stained within HER-2 and Anti-Pan Cytokeratin staining. As the images showed there 
were exact boundary between metastases and healthy tissue in sample M1 JIMT with 
HER-2 staining and as well as with Anti-Pan Cytokeratin staining. In both samples, the 
cells of the metastases are clearly larger than the cells of the lung tissue and in metas-
tasis cell size have variation. 
5.3.3 236 2/B JIMT 
HER-2 and Anti-Pan Cytokeratin staining results of sample 236 2/B JIMT are described 
below and shown by figures. 
 
 Sample 236 2/B JIMT. HER-2 staining.  
Result of Sample 236 2/B JIMT HER-2 staining is negative because the staining result 
is completely blue. There is clearly shown metastasis in Figure 8, image 1 is overview, 
image 2 is zoomed in metastasis and image 3 is zoomed more closely. The cellular 
structure of this metastasis is clearly denser, and the cells are larger than elsewhere in 
the sample. The cells are grouped together which is characteristic of cancerous tumors, 
but it is noticeable that cell size variation is not that markable.  
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  Sample 236 2/B JIMT. Anti-Pan Cytokeratin staining.  
In Anti-Pan Cytokeratin staining samples 236 2/B result is positive. The staining result is 
not strongly positive but as image 2 in figure 9 shows there is brown color in the tumor 
and that means that there is some cytokeratins in the structure. The metastasis cell size 
is bigger than elsewhere in the lung tissue and the cells are more densely organized. 
In sample 236 2/B JIMT is noticeable that cell size variation is not that markable. Both 
staining’s are supporting that fact. Compared to samples 218 TUMOR LUC and M1 JIMT 
LUC the variation of cell size is much less in sample 236 2/B JIMT. It is also HER-2 
negative which could support the fact that HER-2 expression in a cell’s surface increases 
cells growth.  
5.3.4 236 1/L JIMT 
The staining result of sample 236 1/L JIMT Anti-Pan cytokeratin is shown below. 
 
 236 1/L JIMT. Anti-Pan Cytokeratin staining. 
Figure 10 is shown sample 236 1/L JIMT Anti-Pan cytokeratin staining and the result is 
negative. The image 1 is overall and image 2 is zoomed which is shown better the stain-
ing result and cellular structure is characteristic to lung tissue. It is blue and it means 
negative result and that there is none of the cytokeratins.  
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5.3.5 235 JIMT 
Sample 235 JIMT was negative in, HER-2 and Anti-Pan Cytokeratin staining. I have 
shown figures of both staining results and describe them in greater detail below. 
 
 Sample 235 JIMT. Images 1. and 2. Are with HER-2 staining. Image 3. Is with Anti-
Pan Cytokeratin staining.  
In figure 11 Sample 235 JIMT the first two images are from HER-2 staining and image3 
is from Anti-Pan Cytokeratin staining. As figure 11 shows the result of HER-2 staining 
was light and it is entirely blue so that means the result is negative. Images 1 and 2 are 
from different slides because I stained many of them. However, result is negative and no 
negatively stained metastasis is visible in the figure 11 indicating that there are no me-
tastases in this sample. Anti-Pan Cytokeratin staining result was negative too but there 
is shown some brownish epitopes in the sample. Consequently, the sample 235 JIMT is 
negative for both antibodies. 
 
 235 JIMT. Anti-Pan Cytokeratin staining. Image 3 from Figure 11. 
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The figure 12 shows that in this staining had a cross reaction. It should be completely 
blue, but some lightly brown epitopes are visible, and no metastasis is shown. This is the 
same image, which is in figure 11, image 3. The cross-reaction occurs throughout the 
tissue sample. It is not in any specific spot nor place where the dye has concentrated 
clearly. I made the Anti-Pan Cytokeratin staining for this sample two times with the same 
concentration and incubation time and the result was the same at both times. It is possi-
ble that in this sample mice tissue had some similar antigens and antibody was binding 
to them. 
235 JIMT sample had cross-reaction and it is possible that antibody was shown an affin-
ity for identical or similar epitopes in mice lung tissue. Cross-reactivity was only detected 
in this sample and it was stained at the same time with other samples, indicating that it 
is not a staining error nor dependent on antibody concentration.  
5.3.6 234 JIMT 
Here is shown HER-2 staining result of sample 234 JIMT. Since I had a few technical 
problems the picture of Anti-Pan Cytokeratin staining is missing from this work. I have 
done it and know a result, so I told the result below. 
 
 234 JIMT. HER-2 staining. In images 1. is shown overview of the slide. In image 2 
is shown positive stained metastasis. 
As figure 13 is shown there were one big sized metastasis in the sample 234 JIMT. The 
result is strongly positive, and the staining is smooth. The metastasis in image 2 is cir-
cular, with a precise boundary and a dense structure. On the other side of the metastasis 
is a portion that is stained negative but belongs to the same tumor. Cell structure in this 
metastasis is dense and there are variations in cell sizes and shapes. Samples 234 JIMT 
Anti-Pan cytokeratin staining result is negative, but the metastasis is clearly distinguished 
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in the image. Unfortunately, because of some technical problems that image is missing, 
but it is available from Biomedicum. 
6 Discussion 
6.1 Results review and conclusions 
HER-2 and cytokeratins are biomarkers that have been used in cancer and tumor diag-
nostics. HER-2 biomarker has been commonly used to help with the prognosis and as-
sessment of cancer treatments to avoid mortality. HER-2 positive cancer is a more ag-
gressive disease, with a higher relapse rate and increased mortality. (Gutierrez — Schiff 
2011.) Consequently, we detected HER-2-positive cells in the mouse lungs, and those 
are from the human JIMT-1 breast cancer cell line that metastasized the mouse lung. In 
this work, there were three samples which were positive to HER-2. HER-2 positive 
stained metastases support the finding that HER-2 positive breast cancer is metastatic, 
and it inevitably affects the choice of cancer drugs.  
HER-2 positivity indicates that cancer has a poor prognosis and is usually metastatic 
(Gutierrez — Schiff 2011). It shows in these staining, and the expression of metastases 
in the samples also indicates that HER-2-positive cancer is prone to metastasis. Metas-
tases with HER-2 positivity are clearly from the JIMT-1 human cancer cell line. Since the 
HER-2 antibody was specific for human HER-2 expression, it is then clear that it is of 
human origin. Cytokeratin positivity supports poor prognosis but can also help in cancer 
treatment planning and drug selection as well as HER-2 (Karantza 2011). If the specific 
cytokeratin is known, it could help with localizing the primary tumor and assessing the 
response to drug therapy.  
Anti-Pan Cytokeratin staining did not give as strong positive results as HER-2 staining, 
but as the controls showed, their positive control stained in the same manner as the 
positive samples. Because cytokeratins appear more accurately at the edges of metas-
tases and, the example in smaller tumors, it may be possible that the cells are at different 
stages and express cytokeratins more strongly. All the sample slides are stained well 
when I compared them to the controls. During this work, a few staining failed, and it was 
likely that the failed slide dried too much during the antibody incubation phase, as the 
dye had accumulated as clumps on the slides. However, I repeated all the failed staining 
and did not use the failed images in my results.  
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The results of different samples indicate differences in metastases and the expression 
of HER-2 and Cytokeratin antigens used. All positively stained metastases shown in the 
figures have shown that the cell distribution of metastases is typical of cancer. Cancer 
cells are more tightly organized, and there are variations in cell sizes. The structure of 
the lung tissue is looser and fibrillary reticulated than the structure of the metastases, 
and it is visible in all images containing tumors. It is clear that metastases expressing the 
HER-2 antigen are from the JIMT-1 human breast cancer cell line. HER-2 antibody is 
specific for human epidermal growth factor 2, and the positive result of HER-2 staining 
is telling that it is human-based. Also, the Anti-Pan Cytokeratin antibody was specific to 
human cytokeratins, so all positive stained samples are from the JIMT-1 human breast 
cancer cell line. There was some cross-reactivity with anti-Pan cytokeratin staining, but 
the cross-reactions were distinguishable and could not have been confused with posi-
tively stained metastatic tumors. 
6.2 Recommendations and further research 
Breast cancers are classified into basic subtypes such as Luminal A, Luminal B, HER-
2+ and basal-like and there are also mixed types of them. (Bray. et. al. 2018; Gutierrez 
— Schiff. 2011; Martin-Castillo et. al. 2015.) In cancer, cytokeratins are used as tumor 
markers in diagnostics because malignant tumors partially maintain specific keratin pat-
terns associated with the original cells. Cytokeratins can be used to determine, for ex-
ample, the prognosis of breast cancer and the tumor aggressiveness of cancer. 
(Gutierrez — Schiff. 2011; Karantza. 2011.) The basal HER2 + phenotype tumor, which 
expresses basal CK5 and CK6 in immunohistochemical staining, has been studied to be 
associated with aggressive disease, poor overall prognosis and predicted worsened dis-
ease-free survival. (Martin-Castillo et. al. 2015.) In the study Martin-Castillo et. al. (2015) 
concludes also that aggressive basal 2-HER2 + tumors that are positive for CK5 and 
CK6 are unlikely to respond to trastuzumab-based adjuvant or neoadjuvant therapy. 
(Gutierrez — Schiff. 2011) In the study by Chung et al. (2016) have also shown that 
Basal-HER2 + tumors are more likely to be resistant to trastuzumab and are associated 
with poorer survival. In the study, they are suggested that CK5 and CK6 expression is 
correlated with EGFR expression. Therefore, Martin-Castillo et. al. (2015) study and 
Chung et. al. (2016) study support each other. In this work, anti-Pan cytokeratin staining 
includes CK1, CK3, CK4, CK5, CK6, CK8, CK10, CK14, CK15, CK16, and CK19 and 
samples 218 JIMT, 236 2 / B JIMT, and M1 JIMT were positive for all or some of the 
above cytokeratins. As a result, it is not possible at this stage to distinguish which specific 
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cytokeratins are positive in these tissue samples, and if specific cytokeratins are to be 
determined, it will require other methods and thus further studies. 
Cytokeratins are associated with deformability and invasive abilities, indicating that cy-
tokeratins may influence cell shape and migration through interactions with the extracel-
lular environment. Expression of cytokeratins CK8/CK18 may increases invasion, cellu-
lar adhesion and metastasis of breast cancer cells. In the study Karantza (2011) has 
presented that elevated CK8 levels may actively reduce the response to cancer treat-
ment and together CK8 with breast cancer resistant protein may increase drug re-
sistance, through different mechanisms. CK8 expression in breast cancer may also de-
termine the aggressiveness of the tumor and it may decrease response to the cancer 
treatments. Gusterson et. al (2005) state in their study that CK17 regulates cell size and 
growth and is used to distinguish myoepithelial cells from luminal epithelium cells and 
CK17 expression in breast tumors is associated with poor prognosis and high tumor 
grade. CK5, CK14 and CK17 expression in breast cancer cells is also shown to be as-
sociated with poor prognosis. The data obtained from the studies are fascinating and can 
be utilized if specific cytokeratins are determined from samples.  
6.3 Exploitation of the results 
The use of animal models to understand human diseases following ethical principles is 
important. In the researches of diseases and their drugs, it is essential to be able to 
model the efficacy of the drug and, for example, cellular structures in animal models. (Lei 
— Ren — Wang — Liang — Tang 2016.) The JIMT-1 used is a human breast cancer 
cell line and was injected into mice hoping it would form primary tumors that metasta-
sized to the lungs and this thesis proves it happened. HER-2 and cytokeratins may serve 
as prognostic markers and participate in the assessment of epithelial tumorigenesis as 
well as in the assessment of response to treatment (Karantza 2011; Martin-Castillo et. 
al. 2015). This characterization of the lung metastasis tumors in the lungs of mice will 
help the research group later use this model for studying the effect of different drugs in 
this model. However, the information on the progress of the study is confidential and 
therefore I cannot open it further in this context.  
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6.4 Reliability 
The whole study has followed honesty, general diligence, and accuracy in the research 
work and the recording and presentation of results and the evaluation of studies and their 
results. Regarding laboratory work, especially staining, it is important to follow proper 
work procedures and methods during the study. During the implementation, I worked 
carefully and followed all the instructions of the methods I used. I received IHC staining 
instructions from the research group laboratory and I used Abcam general instructions 
for IHC staining. (Abcam: IHC staining protocol.) During the study, we optimize the Anti-
Pan Cytokeratin staining, which increases the reliability of the results. HER-2 staining 
has been optimized in the past by others. I read the safety instructions for hazardous 
substances used in the work before working. I always wore a lab coat while working and 
nitrile gloves to protect against skin contact when processing hazardous substance. I 
worked in a laminar cabinet while working with hazardous substances such as xylene for 
example. All the hazardous substance waste was disposed of following the hazardous 
substance safety instructions and Biomedicum protocols.  
While working in the laboratory, I wrote everything I did in the lab book and always read 
the instructions before working with the new device. Tissue samples must be properly 
processed before paraffin embedding. Working with mice and collecting and preparing 
the tissue samples was performed by other members of the research group. I did the 
slicing of the tissue sample blocks by myself and if I had any difficulty with the slicing, I 
asked help from Marja Ben-Ami, who has a long experience and expertise in tissue sec-
tions. When performing experimental staining, control samples must be included in all 
experiments for reliability, and thus the correctness of the staining can be ensured. I 
optimize one of the two IHC antigen stains and present control samples to demonstrate 
reliability in chapter 5.2, based on figure 2 and figure 3. The images in this file are pro-
moted and cropped from the original images. All the images in this thesis are available 
in their original size and format. 
6.5 Research ethics 
All the references which I have used in this bachelor’s thesis are from trusted sites. I 
mainly chose fresh sources up to 10 years old, but some sources are older. The older 
sources which I have used are most discussions or basic knowledge that has not 
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changed during the time. Most of the sources are from the National Center for Biotech-
nology Information (NCBI) or Science Direct sites. I used Abcam sites for a source with 
the methods because we were using their products and they got a good IHC protocol 
manual. All the articles which I used for references were free to read. This produce text 
has not been plagiarized, I have checked my thesis with Turnitin-program, and I have 
referred to the used references properly.  
This work has not included any human samples or any patient information. All the used 
specimens are from mice. Human skin control slides are from human skin tissue sample 
block and HUSLAB’s pathology laboratory has given it without any patient information 
nor even knowledge of gender. The pathology laboratory has diagnosed the skin tissue 
to be healthy before giving it to the research group’s laboratory. The results presented in 
this bachelor’s thesis are shown as they are, without changing them to suit better the 
needs. We made a contract between me, the research group, and Metropolia University 
of Applied Sciences and it is signed at the beginning of this process. The research group 
has applied for and obtained all necessary permits before starting the study. I did not 
work with test mice during implementation, I did not even see an animal lab in Biomedi-
cum, but there are a lot of ethical questions involved in the research use of mice. 
Mice are used in medical researches because they have physiologically and phyloge-
netically similarities with humans for example the immune systems are similar. Mice re-
searches have given much information in the adaptive immune system, T-cell receptor 
and understanding of different diseases and medicines during in the past century. (Perl-
man. 2016.) Mice are living creatures, so ethical content is important in mice researches 
and mice should be used in researches only within an ethical frame and under the laws. 
(Festing – Wilkinson 2007.) 
Experiments on mice are scientific and necessary to achieve the research results. In this 
in vivo study mice are immunocompromised to achieve the best results. The research 
group has the needed project license from the national board of animal experiments. 
Always before starting new research that contains a test animal study, it must be ob-
tained. The research will continue further, and its future is related to cancer medicines 
and treatments. This project follows the right ethical principles, responsibility and scien-
tific practice and takes all these into account throughout the research. Scientific practice 
and experimental design help to minimize the use of test mice. (European parliament 
and the council of the European Union. Directive 2010/63/EU; Government Decree on 
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the Protection of Animals Used for Scientific or Educational Purposes. 564/2013; Perl-
man 2016.) 
In Biomedicum the researchers which are using mice in the study and will work with them 
must do the course which gives the right to perform animal-related measures, design 
projects and procedures, to care for animals and killing animals. The course gives the 
right to work according to Act 497/2013, Decree 564/2013 and Directive 2010/63/EU. In 
Finland, the use of animals for research purposes is strictly regulated by law. Law 
564/2013 lays down precise requirements for the facilities and operation of a laboratory 
for the use of animals that support the ethical treatment of animals. (Government Decree 
on the Protection of Animals Used for Scientific or Educational Purposes 564/2013; Eu-
ropean parliament and the council of the European Union. Directive 2010/63/EU; Uni-
versity of Helsinki. LAS education and training 2020.) The European Union’s Directive 
applies to all its Member States and Directive 2010/63/EU establishes the principles of 
replacement, reduction, and refinement. In principle, it is specified that the Member 
States shall ensure that: 1. Whenever possible, a reliable method or test strategy which 
does not include experimental animals shall be used. 2. The project should use as few 
experimental animals as possible without compromising its objectives. 3. The breeding, 
accommodation, care, and measures of experimental animals shall be carried out in such 
a way as to avoid or minimize the pain, suffering, distress and lasting harm to the ani-
mals. (Hobson-West 2016.) 
6.6 Professional growth 
The bachelor’s thesis process started in the spring of 2019. I met Mark Barok for the first 
time at Biomedicum, Helsinki, in the fall of 2019. During the meeting, I got an introduction 
to the research of the research group and received the topic for my thesis. After receiving 
the topic, I started to explore and get to know the subject better and started writing a plan 
and gathering a theoretical knowledge base. The thesis was implemented between Oc-
tober 2019 and February 2020. 
The methods and professional foundations learned in the laboratory work and during this 
degree supported me in doing this work. Particularly useful was a basic knowledge of 
laboratory work and principles of immunohistochemical staining. Immunohistochemistry 
was the main method in this work and all the performed tasks in the laboratory were 
related to it. Staining is the basic method used by a Biomedical Laboratory Scientists. 
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The skills and knowledge learned during the clinical histology and molecular genetics 
research course also proved useful in the thesis implementation. There are many basic 
methods used by research groups and it is easy to implement them with the profession 
and knowledge of a biomedical laboratory scientist. Therefore, research groups also 
need the profession of Biomedical Laboratory Scientist because they have a basic 
knowledge of the clinical laboratory methods, their use and basic knowledge of natural 
sciences and technology. However, working in a research environment differs in many 
ways from a basic clinical laboratory and it has been comprehensive to see such an 
employment opportunity as well. I learned a lot about working day planning and sched-
uling, as well as what tasks a biomedical laboratory scientist can have when working in 
a research team. 
7 Acknowledgements 
I want to express my gratitude to Mark Barok, for giving the topic to my thesis and guiding 
and helping me throughout the process. I would also like to thank all the members of the 
research group, you received me well and provided help when I needed it. I received 
professional guidance and advice throughout the process. I want to thank Marja Ben-
Ami for guiding me in the laboratory work and helping me whenever I needed. I'm de-
lighted and I appreciate receiving this experience of research work. I developed a lot 
professionally during the process and I got responsibility during the work and that taught 
me a lot.  
  
34 
 
References 
Abcam. Anti-Pan Cytokeratin Antibody. Web document. <https://www.abcam.com/pan-
cytokeratin-antibody-ab217916.html#top-500> Read 2.2.2020 
Abcam. IHC staining protocol. Web document. <https://www.abcam.com/protocols/im-
munostaining-paraffin-frozen-free-floating-protocol> Read 3.1.2020 
Abcam. IHC-Paraffine. Web Document. <https://www.abcam.com/ps/pdf/proto-
cols/ihc_p.pdf> Read 8.12.2019 
Abcam. Immunohistochemistry. Web Document. <https://www.abcam.com/content/im-
munohistochemistry-the-complete-guide> Read 18.2.2020 
Alberts, Bruce – Bray, Dennis – Hopkin, Karen – Johnson, Alexander – Lewis, Julian – 
Raf, Martin – Roberts, Keith – Walter, Peter 2004. Essential Cell Biology. New York: 
Garland Science. Read 20.9.2019 
American Cancer Society. Oncogenes and tumor suppressor genes. Last Revised: 
2014. Web Document. <https://www.cancer.org/cancer/cancer-causes/genetics/genes-
and-cancer/oncogenes-tumor-suppressor-genes.html> Read 29.3.2020 
Aptum Biologics. Antigen retriever. Web document. <https://www.antigen-re-
triever.com/single-post/2019/05/05/Antigen-Masking-During-Fixation-and-Embedding> 
Read 19.12.2019 
Barok, Mark — Puhka, Maija — Vereb,Gyorgy — Szollosi, Janos — Isola, Jorma – Jo-
ensuu, Heikki. 2018. Cancer-derived exosomes from HER2-positive cancer cells carry 
trastuzumab-emtansine into cancer cells leading to growth inhibition and caspase acti-
vation. BMC Cancer. Vol 18: 504. Available online. 
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5930687/> Read 26.9.2019 
Bray, Freddie — Ferlay, Jacques — Soerjomataram, Isabelle — Siegel, Rebecca — 
Torre, Lindsey — Jemal, Ahmedin 2018. Global cancer statistics 2018: GLOBOCAN 
estimates of incidence and mortality worldwide for 36 cancers in 185 countries. A Can-
cer Journal for Clinicians. Vol 68 (6): 387-506. Available online. <https://acsjour-
nals.onlinelibrary.wiley.com/doi/full/10.3322/caac.21492> Read 25.3.2020 
Chial, Heidi 2008. Proto-oncogenes to oncogenes to Cancer. Web Document. 
<https://www.nature.com/scitable/topicpage/proto-oncogenes-to-oncogenes-to-cancer-
883/> Read 28.3.2020 
Cho, Nariya 2016. Molecular subtypes and imaging phenotypes of breast cancer. Ultra-
sonography. Vol 35(4): 281-288. Available online. 
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5040136/> Read 25.3.2020 
Chung, A —Choi, M —Han, B — Bose, S — Zhang, X —Medina-Kauwe, L —Sims, J 
— Murali, R — Taguiam, M — Varda, M — Schiff, R — Giuliano, A — Cui, X. 2016. 
35 
 
Basal protein expression is associated with worse outcome and trastuzamab re-
sistance in Her2+ invasive breast cancer. Clinical Breast Cancer. Vol 15(6): 448–457. 
Available online. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4644726/> Read 
10.3.2020 
Duraiyan, Jeyapradha — Govindarajan, Rajeshwar —Kaliyappan, Karunakaran — Pa-
lanisamy, Murugesan 2012. Applications of immunohistochemistry. Dental Science. Vol 
4(6): 307-309. Available online. <https://www.ncbi.nlm.nih.gov/pmc/arti-
cles/PMC3467869/> Read 28.3.2020 
European Parliament and the Council of the European Union. Directive 2010/63/EU. 
Set at 22 September 2010. <https://eur-lex.europa.eu/LexUriServ/LexUriS-
erv.do?uri=OJ:L:2010:276:0033:0079:FI:PDF> Read 8.2.2020 
Festing, Simon — Wilkinson, Robin 2007. The ethics of animal research. Talking Point 
on the use of animals in scientific research. Web document. EMBO Rep. Vol 8(6): 526-
530. Available online. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2002542/> Read 
30.1.2020 
Government Decree on the Protection of Animals Used for Scientific or Educational 
Purposes. 564/2013. Set at Helsinki, 18 July 2013. <https://www.finlex.fi/en/laki/kaan-
nokset/2013/en20130564.pdf> Read 28.1.2020. 
Gusterson, Barry — Ross, Douglas — Heath, Victoria – Stein, Torsten 2005. Basal cy-
tokeratins and their relationship to the cellular origin and functional classification of 
breast cancer. Web Document. <https://breast-cancer-research.biomedcentral.com/ar-
ticles/10.1186/bcr1041> 10.12.2019 
Gutierrez, Carolina — Schiff, Rachel 2011. HER-2. Biology, Detection and Clinical Im-
plications. Arch Pathol Lab Med. 2011 Jan; 135(1): 55–62. Available online. 
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3242418/> Read 2.12.2019  
Hobson-West, Pru 2016. Ethical boundary-work in the animal research laboratory. So-
ciology. Vol 46(4): 649–663. Available online. <https://www.ncbi.nlm.nih.gov/pmc/arti-
cles/PMC5047351/> Read 15.1.2020 
IHCWORLD. Peroxidase. <http://www.ihcworld.com/_technical_tips/peroxi-
dase_tips.htm> Read 9.12.2019 
International Agency for Research on Cancer 2018. Latest global cancer data: Cancer 
burden rises to 18.1 million new cases and 9.6 million cancer deaths in 2018. Web 
Document. <https://www.iarc.fr/wp-content/uploads/2018/09/pr263_E.pdf> Read 
10.1.2020 
Karantza, V. 2011. Keratins in health and cancer. Oncogene. Vol 30(2): 127–138. 
Available online. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3155291/> Read 
5.3.2020 
36 
 
Lei, Zhen-ge — Ren, Xiao-hua — Wang, Sha-sha — Liang, Xin-hua — Tang, Ya-ling 
2016. Immunocompromised and immunocompetent mouse models for head and neck 
squamous cell carcinoma. OncoTargets and Therapy. Volume 2016(9): 545-555. Avail-
able online. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4734789/> Read 5.4.2020 
Luongo De Matos, Leandro —Trufelli, Damila Cristina — Luongo de Matos, Maria 
Graciela — Da Silva Pinhal, Maria Aparecida 2010. Immunohistochemistry as an Im-
portant Tool in Biomarkers Detection and Clinical Practice. Biomark Insights. Vol 5: 9-
20. Available online. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2832341/> Read 
10.3.2020 
Martin, Tracey A. — Ye, Lin — Sanders, Andrew J. — Lane, Jane — Jiang, Wen G. 
2013. Cancer invasion and metastasis: Molecular and Cellular Perspective. Landes Bi-
oscience ©2013. Available online. <https://www.ncbi.nlm.nih.gov/books/NBK164700/> 
Read 20.1.2020 
Martin-Castillo, Begoña —Lopez-Bonet, Eugeni — Buxó, Maria — Dorca, Joan — 
Tuca-Rodríguez, Francesc —Alonso Ruano, Miguel — Colomer, Ramon — Menendez, 
Javier A 2015. Cytokeratin 5/6 fingerprinting in HER2-positive tumors identifies a poor 
prognosis and trastuzumab-resistant Basal-HER2 subtype of breast cancer. Oncotar-
get. Vol 6(9): 7104-7122. Available online. <https://www.ncbi.nlm.nih.gov/pmc/arti-
cles/PMC4466672/> Read 20.3.2020 
Meric-Bernstam, Funda — Hung, Mien-Chie 2006. Advances in Targeting Human Epi-
dermal Growth Factor Receptor-2 Signaling for Cancer Therapy. Clinical Cancer Re-
search- Vol 12(21): 6326-6330. Available online. <https://clincancerres.aacrjour-
nals.org/content/12/21/6326.long> Read 26.2.2020 
Minot, Douglas — Voss, Jesse — Rademacher, Susan — Lwin, Toe –– Orsulak, Jes-
sica — Caron, Bolette — Ketterling, Rhett — Nassar Aziza — Chen, Beiyun — Clay-
ton, Amy. 2012. American Journal of Clinical Pathology. Vol 137(2): 270-276. Available 
online. <https://academic.oup.com/ajcp/article/137/2/270/1761010> Read 10.3.2020 
Mitri, Zahi — Constantine, Tina — O’Regan, Ruth 2012. The HER2 Receptor in Breast 
Cancer: Pathophysiology, Clinical Use, and New Advances in Therapy. Chemotherapy 
Research and Practice. 2012: 743193. Available online. 
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3539433/> Read 25.2.2020 
Moasser, Mark. M. 2011. The oncogene HER2; Its signaling and transforming functions 
and its role in human cancer pathogenesis. Oncogene Vol 26(45): 6469-6487. Availa-
ble online. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3021475/> Read 29.3.2020 
Paulsen, I.M.S — Dimke, H. – Frische, S. 2015. A Single Simple Procedure for Dewax-
ing, Hydration and Heat-Induced Epitope Retrieval (HIER) for Immunohistochemistry in 
Formalin-Fixed Paraffin-Embedded Tissue. European Journal oh Histochemistry. Vol 
59(4): 2532. Available online. <https://www.ncbi.nlm.nih.gov/pmc/arti-
cles/PMC4698609/> Read 6.3.2020 
37 
 
Perlman, L. Robert. 2016. Mouse models of human disease. Evolution, Medicine & 
Public Health. Vol 2016(1): 170–176. Available online. 
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4875775/> Read 10.11.2019 
Rechavi, Oded — Goldstein, Itamar — Vernitsky, Helly — Rotblat, Barak — Kloog, 
Yoel 2007. Intracellular Transfer of Oncogenic H-Ras at the Immunological Synapse. 
PLoS ONE. Vol 2(11): e1204. Available online. <https://www.ncbi.nlm.nih.gov/pmc/arti-
cles/PMC2065899/> Read 5.2.2020 
Schweizer, Jürgen — Bowden, Paul —Coulombe, Pierre —Langbein, Lutz —Lane, Bir-
gitte — Magin, Thomas — Maltais, Lois —Omary, Bishr —Parry, David — Rogers, Mi-
chael —Wright, Mathew 2006. New consensus nomenclature for mammalian keratins. 
Journal of Cell Biology. Vol 174(2): 169–174. Available online. 
<http://jcb.rupress.org/content/174/2/169>11.12.2019 
Seyfried, Thomas — Huysentruyt, Leanne 2014. On the origin of cancer metastasis. 
Critical Reviews in Oncogenesis. Vol 18(1-2): 43–73. Available online. 
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3597235/> Read 19.3.2020 
Slamon, D. — Leyland-Jones, B. —Shak, S. —Fuchs, H. — Paton, V. — Bajamonde, 
A. — Fleming, T. — Eiermann, W. — Wolter, J. —Pegram, M. — Baselga J. — Norton, 
L. 2001. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic 
breast cancer that overexpresses HER2. N Engl J Med. Vol 344(11): 783-792. Availa-
ble online. 
<https://www.nejm.org/doi/10.1056/NEJM200103153441101?url_ver=Z39.88-
2003&rfr_id=ori%3Arid%3Acrossref.org&rfr_dat=cr_pub%3Dwww.ncbi.nlm.nih.gov> 
Read 15.4.2020 
Tanner, Minna —. Kapanen, Anita I — Junttila, Teemu — Raheem, Olayinka — Gren-
man, Seija — Elo, Jussi — Elenius, Klaus — Isola, Jorma 2004. Characterization of a 
novel cell line established from a patient with Herceptin-resistant breast cancer. Ameri-
can Association for Cancer Research. Vol 3(12): 1585-1592. Available online. 
<https://mct.aacrjournals.org/content/3/12/1585.long> Read 20.2.2020 
Thermo Fisher. Antigen retrieval. Web document. <https://www.ther-
mofisher.com/fi/en/home/life-science/protein-biology/protein-biology-learning-cen-
ter/protein-biology-resource-library/pierce-protein-methods/paraffin-removal-antigen-
retrieval.html> Read 10.12.2019 
ThermoFisher. IHC troubleshoot guide. Web Document. <https://www.ther-
mofisher.com/fi/en/home/life-science/protein-biology/protein-biology-learning-cen-
ter/protein-biology-resource-library/pierce-protein-methods/ihc-troubleshooting-
guide.html> Read 15.3.2020 
University of Helsinki. LAS education and training. Updated 24.1.2020. 
<https://www.helsinki.fi/en/infrastructures/comprehensive-model-organisms/infrastruc-
tures/laboratory-animal-center/las-education-and-training> Read 2.2.2020 
Vector. User guide. 2019. Web Document. <https://vectorlabs.com/media/fo-
lio3/productattachments/protocol/SK-4105.pdf> Read 15.2.2020 
38 
 
World Cancer Research Fund. 2018. The cancer process. Web Document. 
<https://www.wcrf.org/sites/default/files/The-cancer-process.pdf> Read 15.10.2019 
 
          Appendix 1 
 1 (3) 
 
ErbB2 datasheet 
 
          Appendix 1 
 2 (3) 
 
 
          Appendix 1 
 3 (3) 
 
 
 
          Appendix 2 
 1 (4) 
 
Anti-Pan Cytokeratin datasheet 
 
          Appendix 2 
 2 (4) 
 
 
          Appendix 2 
 3 (4) 
 
 
          Appendix 2 
 4 (4) 
 
 
